SCHEMBL5741745

SCHEMBL5741745

O=C(Cc1cc(I)c(O)c(I)c1)NO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
THRA P10827 2/20 0.47
THRB P10828 2/20 0.47
PPARG P37231 2/20 0.47
ITGB3 P05106 1/20 0.47
ITGAV P06756 1/20 0.47
RXRA P19793 1/20 0.47
PCNA P12004 2/20 0.43
HIF1A Q16665 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
PDE4A P27815 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HDAC10 Q969S8 1/20 0.41
TTR P02766 1/20 0.39
MEP1B Q16820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5742384 0.82 HDAC8 (0.47) HDAC6HDAC8MEN1KMT2APCNA
SCHEMBL5740650 0.82 HDAC6 (0.47) HDAC6HDAC8MEN1KMT2ATHRA
SCHEMBL5743421 0.80 HDAC8 (0.42) HDAC6HDAC8MEN1KMT2ATHRA
SCHEMBL11052430 0.79 HDAC6 (0.52) HDAC6HDAC8MEN1KMT2AHIF1A
SCHEMBL8773706 0.77 THRB (0.71) MEN1KMT2ATHRATHRBPPARG
SCHEMBL14485394 0.76 HSP90AB1 (0.66) MEN1KMT2ATHRATHRBPPARG
SCHEMBL5741936 0.76 GAA (0.55) HDAC6HDAC8MEN1KMT2AHIF1A
SCHEMBL10962553 0.75 THRB (0.50) MEN1KMT2ATHRATHRBPPARG
SCHEMBL5743343 0.74 PCNA (0.62) THRATHRBPPARGITGB3ITGAV
SCHEMBL5742684 0.74 EPHX2 (0.49) HDAC6HDAC8KMT2AHIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP claimed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US claimed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP claimed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO claimed
EP-1383729-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2006-04-19 EP disclosed
US-20040267015-A1 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION 2004-12-30 US disclosed
EP-1383729-A1 PEPTIDE DEFORMYLASE INHIBITORS SmithKline Beecham Corporation (US) 2004-01-28 EP disclosed
WO-2002081426-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267015-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 HDAC6 1261/4885HDAC8 2220/4885MEN1 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.